The former management team at MiMedx (NSDQ:MDXG), led by ex-CEO Parker Petit, allegedly enacted a scheme to cook the books at the regenerative medicine company, retaliated against anyone who questioned their sketchy accounting practices and secretly filmed their offices, according to a probe the company launched after the scheme blew up last year. In February 2018, […]
Report: Vericel to supply Epicel-based grafts for baby born without skin
Vericel (NSDQ:VCEL) is growing skin grafts using its Epicel product to help a baby born in Texas without skin, according to a recent Boston Business Journal report. The company said yesterday that it is creating grafts with its Epicel skin replacement product for newborn Ja’bari Gray, who has been in intensive care since being born earlier […]
Histogenics completes transformation into Ocugen with $7m deal for NeoCart
UPDATED May 14, 2019, with comment from Medavate. Histogenics (NSDQ:HSGX) said today that it completed another step on its transformation into clinical-stage biopharmaceutical company Ocugen, with a nearly $7 million deal to sell its NeoCart regenerative knee treatment to Medavate. The $6.5 million all-cash deal, signed May 8, will see all of the NeoCart assets pass […]
Syntellix plans public listing on Singapore exchange
German orthopedic implant maker Syntellix said today that it’s planning an initial public offering on the Singapore Stock Exchange and named a new CFO. Syntellix makes screws and pins from a magnesium-based material it developed, called Magnezix, that’s designed to be resorbed and converted into bone over time. Its products are approved in Mexico, Vietnam […]
Vericel inks licensing deal for MediWound’s NexoBrid, posts Q1 earnings
Vericel (NSDQ:VCEL) said yesterday it inked an exclusive U.S. licensing and supply agreement with MediWound (NSDQ:MDWD) for its NexoBrid biological product, and reported first quarter earnings that missed expectations on Wall Street. The NexoBrid is a topically-administered product intended to enzymatically remove nonviable burn tissue in patients with deep partial and full-thickness thermal burns. The product has […]
Misonix puts up $97m in stock for Solsys Medical
Misonix (NSDQ:MSON) said yesterday that it put $97 million in stock on the table for Solsys Medical, formerly Soluble Systems, and its TheraSkin regenerative wound dressing. The deal calls for Farmingdale, N.Y.-based Misonix to issue 5.7 million new shares to Solsys stockholders, which would leave MSON investors owning 64% of the new company and former Solsys […]
Smith & Nephew closes Osiris Therapeutics, Leaf Healthcare buys
Smith & Nephew (NYSE:SNN) said today that it closed both its $660 million acquisition of Osiris Therapeutics (NSDQ:OSIR) and its purchase of Leaf Healthcare and its Leaf Patient Monitoring System. The London-based company said that it paid $19 per share in cash for Osiris, which develops and produces regenerative medicine products including skin, bone grafts and articular […]
TissueTech raises $55m
TissueTech has raised approximately $55.3 million in a new round of equity financing, according to a recently posed SEC filing. The Doral, Fla.-based company makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (its Bio-Tissue subsidiary) and musculoskeletal conditions and wound care (its Amniox Medical business). Money in the round came […]
Admedus deals vaccines biz to Constellation Therapeutics
Admedus (ASX:AHZ) said today that it agreed to sell its vaccines business to Constellation Therapeutics in a deal that will see it own nearly 30% of the Chinese company. Other shareholders in the vaccines would own another 11%, Queensland, Australia-based Admedus said. Sun Bright Holdings will own the remainder and put in $18 million until November […]
Prellis Biologics raises $9m
Prellis Biologics has raised $8.7 million in a new round of equity financing, according to a recently posed SEC filing. The San Francisco-based company is developing ultra-fast high-resolution holographic laser printing technology intended for use in creating human organs and tissues, according to its website. Prellis Biologics offers a number of products based around vascularized […]
Osiris shareholders sue to block $660m merger with Smith & Nephew
A group of Osiris Therapeutics (NSDQ:OSIR) shareholders is suing to block its $660 million acquisition by Smith & Nephew (NYSE:SNN) because the purchase price is too low. Earlier this month the British orthopedics and wound care giant put $19 per share on the table to acquire Osiris and its regenerative medicine portfolio, representing a 37% premium on the 90-day […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 52
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube